Ayten Saracoglu1,2, Mehmet Ezelsoy3, Kemal Tolga Saracoglu4. 1. Department of Anesthesiology and Intensive Care, Istanbul Marmara University Medical School, Istanbul, Turkey. anesthesiayten@gmail.com. 2. Marmara University Medical School Fevzi Cakmak Mah, Muhsin Yazicioglu Cad. No:10 34899 Ust Kaynarca Pendik, Istanbul, Turkey. anesthesiayten@gmail.com. 3. Department of Cardiovascular Surgery, Istanbul Bilim University Medical School, Istanbul, Turkey. 4. Department of Anesthesiology and Intensive Care, Health Sciences University Medical School, Istanbul, Turkey.
Abstract
BACKGROUND: Following the administration of tranexamic acid, the occurrence of thromboembolic events is a controversial issue. AIMS: In this retrospective cohort study, we aimed to determine the possible thromboembolic complications due to tranexamic acid as a prophylactic method in patients undergoing open heart surgery. METHODS: The data of 172 adult patients undergoing open heart surgery were analyzed. All patients received tranexamic acid at a dose of 50 mg/kg. The patients were divided into 3 groups as multiple-valve surgery (group 1), coronary bypass alone (group 2), and coronary bypass with valve surgery (group 3). The amount of blood transfusion, bleeding in intra- and postoperative period, and the presence of thromboembolic events including myocardial infarction, stroke, pulmonary embolism, and deep vein thrombosis were investigated. RESULTS: Patient demographics and duration of surgery were not significantly different in groups (p > 0.05). Hb, Htc, INR, and platelet levels of all groups did not differ significantly (p > 0.05). In total, 7 patients underwent reexploration. Postoperative DVT, stroke, and seizure were not seen at all. There was no statistically significant difference between groups in terms of the amount of blood transfusion, drainage, or peritoneal hematoma. The length of hospital stay and the mortality rate did not differ (p > 0.05). CONCLUSIONS: In patients receiving tranexamic acid infusion at 50 mg/kg dose, reexploration rates remained at 4.1% even after major cardiac surgeries. No thrombosis, stroke, or seizure were reported. Our findings support that tranexamic acid is a safe drug which has positive effect on reducing perioperative bleeding.
BACKGROUND: Following the administration of tranexamic acid, the occurrence of thromboembolic events is a controversial issue. AIMS: In this retrospective cohort study, we aimed to determine the possible thromboembolic complications due to tranexamic acid as a prophylactic method in patients undergoing open heart surgery. METHODS: The data of 172 adult patients undergoing open heart surgery were analyzed. All patients received tranexamic acid at a dose of 50 mg/kg. The patients were divided into 3 groups as multiple-valve surgery (group 1), coronary bypass alone (group 2), and coronary bypass with valve surgery (group 3). The amount of blood transfusion, bleeding in intra- and postoperative period, and the presence of thromboembolic events including myocardial infarction, stroke, pulmonary embolism, and deep vein thrombosis were investigated. RESULTS:Patient demographics and duration of surgery were not significantly different in groups (p > 0.05). Hb, Htc, INR, and platelet levels of all groups did not differ significantly (p > 0.05). In total, 7 patients underwent reexploration. Postoperative DVT, stroke, and seizure were not seen at all. There was no statistically significant difference between groups in terms of the amount of blood transfusion, drainage, or peritoneal hematoma. The length of hospital stay and the mortality rate did not differ (p > 0.05). CONCLUSIONS: In patients receiving tranexamic acid infusion at 50 mg/kg dose, reexploration rates remained at 4.1% even after major cardiac surgeries. No thrombosis, stroke, or seizure were reported. Our findings support that tranexamic acid is a safe drug which has positive effect on reducing perioperative bleeding.
Authors: Joshua Montroy; Brian Hutton; Preveshen Moodley; Nicholas A Fergusson; Wei Cheng; Alan Tinmouth; Luke T Lavallée; Dean A Fergusson; Rodney H Breau Journal: Transfus Med Rev Date: 2018-02-19
Authors: Chantal L I Gielen; Anneke Brand; Waander L van Heerde; Theo Stijnen; Robert J M Klautz; Jeroen Eikenboom Journal: Thromb Res Date: 2015-12-29 Impact factor: 3.944
Authors: Steven M Frank; Rajiv N Thakkar; Stanley J Podlasek; K H Ken Lee; Tyler L Wintermeyer; Will W Yang; Jing Liu; Leo C Rotello; Thomas A Fleury; Pat A Wachter; Lisa E Ishii; Renee Demski; Peter J Pronovost; Paul M Ness Journal: Anesthesiology Date: 2017-11 Impact factor: 7.892
Authors: Yoan K Kagoma; Mark A Crowther; James Douketis; Mohit Bhandari; John Eikelboom; Wendy Lim Journal: Thromb Res Date: 2008-11-12 Impact factor: 3.944